Background-Clinical observations of migraine headache symptoms in patients with a patent foramen ovale (PFO), both of which conditions are highly prevalent, have raised the question of a possible pathophysiological relationship. We sought to evaluate the assumption of an association between migraine headaches and the presence of PFO by use of a large case-control study. Methods and Results-We conducted a case-control study to assess the prevalence of PFO in subjects with and without migraine. Case subjects were those with a history of migraine (diagnosed by neurologists at a specialty academic headache clinic). Control subjects were healthy volunteers without migraine 1:1 matched on the basis of age and sex with case subjects. Presence of PFO was determined by transthoracic echocardiogram with second harmonic imaging and transcranial Doppler ultrasonography during a standardized procedure of infused agitated saline contrast with or without Valsalva maneuver and a review of the results by experts blinded to case-control status. PFO was considered present if both studies were positive. Odds ratios were calculated with conditional logistic regression in the matched cohort (nϭ288). In the matched analysis, the prevalence of PFO was similar in case and control subjects (26.4% versus 25.7%; odds ratio 1.04, 95% confidence interval 0.62 to 1.74, Pϭ0.90). There was no difference in PFO prevalence in those with migraine with aura and those without (26.8% versus 26.1%; odds ratio 1.03, 95% confidence interval 0.48 to 2.21, Pϭ0.93). Conclusions-We found no association between migraine headaches and the presence of PFO in this large case-control study. (Circulation. 2010;121:1406-1412.)
M igraine headache is a chronic disabling condition that affects approximately 6% of men and 15% to 18% of women. [1] [2] [3] Its peak prevalence is in midlife, and the condition may result in significant functional impairment and loss of productivity and is associated with high healthcare costs. 1 Migraine headache may be preceded by an aura, a neurological disturbance, most commonly visual or sensory, with subsequent complete recovery. Migraine is thought to be caused by both hereditary and environmental factors and is believed to have neurogenic and neurovascular components to its origin, but its pathophysiology remains incompletely understood. Patent foramen ovale (PFO) is a slitlike interatrial defect that is quite common in the general population, with a prevalence of approximately 10% to 25% depending on the population studied and the method-ology used for diagnosis. 4 -7 It occurs with equal frequency in men and women and tends to decrease in frequency with age.
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Observational studies have concluded that a lower frequency of migraine attacks occurred after PFO closure for cryptic stroke, whereas others have postulated a relationship between shunt magnitude and migraine attacks. 8 -16 Thus, a hypothesis has emerged that a PFO and the associated intracardiac right-to-left shunt of vasoactive substances or microemboli from the venous to cerebral arterial circulation may allow the triggering of a migraine attack. 17 One randomized study of a PFO closure device has been performed that showed no significant reduction in the primary end point of migraine attack frequency in those who had the device intervention. 18 Another method to test the relationship between PFO and migraine more generally is to test the prevalence association. If there is a role of PFO in the causation of a migraine headache that justifies targeted intervention, such as closure or pharmaceutical prophylaxis, then this common condition (PFO) should be more prevalent among migraineurs. We used the casecontrol method to test the epidemiological association between these 2 conditions.
Methods

Study Design
The aim of the study was to evaluate the association between migraine headaches and the presence of PFO by use of a matched case-control design with prospective data collection. Case subjects were identified from the headache center of Beth Israel Deaconess Medical Center. This outpatient clinic is staffed by neurologists specializing in the treatment of headache and pain syndromes. Case subjects who met the inclusion criteria and had no exclusions were identified as having a history of migraine with or without aura and enrolled in the present study.
Study Population
Case subjects met all of the following inclusion criteria to be eligible for enrollment: Age 18 to 65 years; onset of migraine before the age of 50 years; and a history of migraine as defined by International Headache Society Classification, either "migraine without aura" (5 or more attacks within the past year that fulfilled all of the following: headache duration 4 to 72 hours; unilateral; pulsating; moderate to severe intensity; aggravation by routine physical activity; and associated symptoms of nausea, vomiting, photophobia, and phonophobia) or "migraine with aura" (5 or more attacks within the past year that fulfilled 3 of 4 criteria: 1 or more fully reversible aura symptom [visual, sensory, motor, speech, or other], gradual onset of at least 1 aura, aura duration of Ͻ60 minutes, and headache, if present, beginning before, with, or after aura within 60 minutes). To avoid the inclusion of subjects likely to have an existing PFO for reasons other than migraine alone, subjects with a known history of cerebrovascular disease, paradoxical embolism, or decompression illness were specifically excluded. Also excluded were those with a history of intracranial hemorrhage, intracranial mass, seizure disorder, organic central nervous system disease, headache as a result of traumatic head or neck injury, alcohol or substance abuse, uncontrolled hypertension, or known pregnancy.
Potential control subjects were selected from the healthy volunteer registry maintained by the Brigham and Women's Hospital. Control subjects were healthy volunteers without a history of migraine matched with case subjects on the basis of age and sex. Specific exclusion criteria for control subjects were any history of migraine as defined by case-inclusion criteria above, chronic daily headache, tension headache occurring more than once per month, prior cerebrovascular disease, history of intracranial hemorrhage, intracranial mass, seizure disorder, organic central nervous system disease, headache as a result of traumatic head or neck injury, alcohol or substance abuse, uncontrolled hypertension, or known pregnancy.
Migraine Frequency and Severity
In addition to information on predefined baseline characteristics, case and control subjects were asked to complete the MIDAS (Migraine Disability Assessment) questionnaire at study baseline, which was repeated after a follow-up period of 3 months. The MIDAS questionnaire is a self-administered instrument that consists of 7 questions assessing headache frequency and severity, as well as the degree of disability. 19, 20 
Detection of PFO
The presence of PFO was determined by 2 ultrasound modalities: Transthoracic echocardiogram (TTE) with second harmonic imaging 21 and transcranial Doppler (TCD) ultrasonography, each evaluated by a single core laboratory blinded to the case or control status of the subject (Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, respectively). TTE was performed in all study subjects according to published guidelines. 22 Agitated saline contrast injection (aerated saline solution) via antecubital vein with provocative maneuvers (standardized Valsalva maneuver, sniff) was used for detection of PFO with right-to-left shunting. A PFO was considered present if any microbubble was seen in the left-sided cardiac chambers within 5 cardiac cycles from maximum right atrial opacification. Right-to-left shunting, if present, was quantified by counting the number of microbubbles in the left atrium during the first 5 cardiac cycles after right atrial opacification. On the basis of the number of microbubbles seen in the left atrium, the degree of shunt was classified as follows: 0, no shunt; 1, mild (1 to 10 microbubbles); 2, moderate (11 to 30 microbubbles); and 3, severe (Ͼ30 microbubbles).
TCD ultrasound was also performed in all study subjects (bilaterally) with a 2-MHz pulsed-Doppler transducer with a multidepth adapter to allow for discrimination between true embolic signals and artifacts. Microembolic signals were defined as characteristic visible and audible short-duration high-intensity signals within the Doppler flow spectrum from the middle and/or anterior cerebral artery. Agitated saline contrast injection (aerated saline solution) via antecubital vein with provocative maneuvers (standardized Valsalva maneuver) was used for detection of PFO with right-to-left shunting. The appearance of at least 1 microembolic signal or high-intensity signal in the middle or anterior cerebral artery within 7 seconds of the injection was considered positive for right-to-left shunting. Classification of degree of shunt on TCD was based on the number of microembolic signals or high-intensity signals in the middle or anterior cerebral artery within 7 seconds of the injection.
PFO was considered to be present if both the TTE and TCD studies were positive for the presence of PFO with right-to-left shunt. As a sensitivity analysis, we also considered the alternate diagnosis of PFO on the basis of either the TTE or TCD study being positive for right-to-left shunt.
Statistical Analysis
The primary end point was the prevalence of PFO. The sample size calculations were based on crude analysis and did not account for any anticipated alteration in power resulting from controlling for confounding factors (because matching on confounders typically leads to an increase in power). Under the assumption of a prevalence of PFO of 15% in control subjects and 30% in case subjects and a 2-sided ␣ level of significance of 0.05, and given a 1:1 comparison, the study had 90% power at a total sample size of 314 (Pearson 2 test for 2 proportions; SAS 9.2, SAS Institute Inc, Cary, NC). The power would remain above 85% in an unmatched sample size of 144 in each group with complete information (total sample size of 288). Prespecified secondary analyses included comparison of PFO prevalence in migraine patients with and without aura, PFO prevalence in those with or without more frequent headaches (Ͼ10 per month), comparison of baseline MIDAS scores in patients with and without PFO, degree of shunting on TTE or TCD, and the presence of migraine.
Continuous variables are reported as meanϮSD or median and interquartile range if not normally distributed, and matched pairs were compared with the paired t test for normally distributed data or Wilcoxon signed rank sum test if highly skewed. Categorical variables are reported as percentages, and the test statistic was based on a Mantel-Haenszel test stratified by matched sets or conditional logistic regression. Data on matched pairs are also presented in a 2ϫ2 table, which shows the concordant and discordant study pairs, with odds ratios (ORs) calculated as the ratio of discordant pairs and the test statistic based on the McNemar test. ORs were calculated with conditional logistic regression before and after adjustment for potential confounding factors. Apart from the matching factors (age and sex), there were no other expected confounders of the association between migraine and PFO, and hence, covariates identified as significant on univariate testing in the matched cohort were considered in the multivariable model; specifically, these included demographic factors (race, ethnicity), family history of cerebrovascular disease, and family history of migraine, stratified on the matching factors of age and sex. We did not adjust for medication used for treatment of migraine. All statistical tests are 2-sided, and PϽ0.05 was considered statistically significant. All analyses were performed with SAS 9.2.
The study was approved by the institutional review boards at the Brigham and Women's and Beth Israel Deaconess Hospitals, and all study participants gave written informed consent. Drs Mauri and Garg had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Study Population
A total of 360 subjects (195 case subjects and 165 control subjects) were enrolled in the study from August 2004 to December 2005. Of these, 314 subjects (156 case subjects and 158 control subjects) underwent diagnostic evaluation for PFO with both TTE and TCD and were analyzed in the present study. Matching on the basis of age and sex yielded 144 control subjects and 144 case subjects for analysis. Case and control subjects were well balanced with respect to matching factors (mean age 41.6 versus 41.4 years, mean difference 0.2 years; 83% of subjects in both cohorts were female; Table 1 ). Migraine with aura was present in 39% of case subjects. Case subjects had significant disability from migraine headaches, with a median baseline MIDAS score of 17 (interquartile range 6 to 36) and 29 days with headache in the prior 3-month period.
Association of PFO and Migraine Headache
In the matched analysis, the prevalence of PFO as diagnosed by both TTE and TCD was similar in case and control subjects (26.4% versus 25.7%; OR 1.04, 95% confidence interval [CI] 0.62 to 1.74, Pϭ0.90; Table 2 ; Figure 1 ). There was no difference in PFO prevalence in those case subjects with migraine with aura and those without (26.8% versus 26.1%; OR 1.03, 95% CI 0.48 to 2.21, Pϭ0.93; Figure 2A ).
Severity of Migraine and PFO Prevalence
We evaluated the association between the severity of migraine headaches and the prevalence of PFO. There was no difference in PFO prevalence in those case subjects with migraine headache frequency of 10 or more per month compared with those with less frequent migraine headaches (26.7% versus 26.3%; OR 1.02, 95% CI 0.46 to 2.27, Pϭ0.96; Figure 2B ). There was also no difference in the mean MIDAS scores in case subjects and control subjects (Pϭ0.55), and median MIDAS scores were actually lower in migraineurs with PFO than in those without (median 9 versus 19, Pϭ0.03; Figure 3 ).
Migraine Headache and Severity of Shunt
A moderate or severe right-to-left shunt on echocardiography was seen in 23 case subjects (16%) compared with 17 control subjects (12%), and there was no association between migraine headache and grade of shunt on TTE (Pϭ0.75). Similarly, there was no association between the mean numbers of microembolic signal hits on TCD in those with migraine and those without (20.5 versus 17.9, Pϭ0.60).
Predictors of Migraine Headache
In an adjusted multivariable model, PFO was not predictive of migraine (Pϭ0.18). Family history of migraine was the strongest independent predictor of migraine (OR 18.6, 95% CI 6.8 to 51.0, PϽ0.001), followed by family history of cerebrovascular disease (OR 2.6, 95% CI 1.1 to 5.8, Pϭ0.03; Table 3 ).
Sensitivity Analysis
In a sensitivity analysis, the prevalence of PFO based on the alternate definition of diagnosis by either TTE or TCD was similar in case and control subjects (OR 1.08, 95% CI 0.69 to 1.69, Pϭ0.73).
Discussion
Clinical descriptions of migraine headache and PFO have raised the possibility of a pathophysiological relationship between these 2 common conditions, yet recent randomized studies of specific closure devices for PFO have not demonstrated a reduction in migraine symptoms. No previous prospective observational studies have been designed to assess whether an association between migraine and PFO in the absence of stroke truly exists, and a single randomized trial of a single device may be limited in its ability to test this general association. We therefore designed and executed a large case-control study using quantitative measures of mi- Figure 1 . PFO prevalence in matched case and control subjects. The prevalence of PFO was similar in patients without migraine (control subjects) and patients with migraine (case subjects). N denotes number in each group. This table displays information about the case-control pairs in the study. Each member of the pair is either exposed or unexposed to the risk factor (PFO presence or absence) and is either a case or control subject, which yields 4 possible outcomes. Pairs with the same exposure status for both case and control are concordant pairs, and pairs with different exposures are discordant pairs. Total number of concordant pairsϭ87; total number of discordant pairsϭ57. OR 1.04 (95% CI 0.62 to 1.74). graine severity and core laboratory assessment to test this association and found no association between migraine headaches and the presence of PFO. The prevalence of PFO as diagnosed by both TTE and TCD was Ϸ26% among individuals with migraine, in those with or without aura, and among individuals without a history of migraine. In addition, we found no association between the severity of right-to-left shunt and migraine or the severity of migraine and the presence of PFO.
Studies involving the use of TCD were the first to report a higher prevalence of right-to-left shunt in patients with migraine, particularly migraine with aura. 9, 10 Other studies investigating the association between cryptogenic stroke and PFO suggested that migraine was more common in those with PFO than in those without. 8 A number of retrospective observational studies of PFO closure for cryptogenic stroke have suggested a possible beneficial effect of PFO closure on migraine frequency and severity, but these studies have been nonblinded and relatively small in sample size. [11] [12] [13] [14] [15] [16] 23, 24 Moreover, in such studies of migraineurs with a previous cryptogenic stroke, the use of aspirin and clopidogrel after PFO closure may have modified migraine frequency and severity. 25 A recent systematic review, although suggesting a potential association between PFO and migraine, also highlighted the low grade of evidence. 16 The underlying mechanism of a possible relationship between migraine and PFO, therefore, remains speculative. It has been postulated that PFO may allow vasoactive biochemicals or microemboli to bypass the lung and reach the cerebral circulation to trigger an attack of migraine, particularly migraine with aura, but if this is so, the precise trigger has not been identified. Indeed, both migraine and PFO are common in the general population, and if this putative mechanism accounts for some cases of migraine, it cannot account for all, because not all migraineurs have a shunt, and not all with a right-to-left shunt have migraine headaches.
A recent cross-sectional study in a population of aged patients (average age 69 years) did not find any association between migraine and PFO diagnosed on TTE. 7 A recent double-blind randomized trial of PFO closure in migraine sufferers found no difference in migraine cessation or prespecified secondary end points between the 2 groups at 6 months 4 ; however, the generalizability of that study beyond the specific device and the patient population eligible for randomization could be limited.
In determining association, observational studies that are prospectively designed and controlled may have important strengths compared with randomized trials. Randomized trials to evaluate a targeted intervention (in this case, closure of PFO) might have the best ability to minimize bias. Yet because the patient population is selective, and because the intervention itself is device specific and subject to specific technical limitations (completeness of closure), randomized studies may not yield a result generalizable to the underlying pathophysiological association. The present study, which was not dependent on a device-specific result, provides important evidence that does not support a general relationship between PFO and migraine and suggests that investigation of alternative, nonvascular causes of migraine may aid in the alleviation and prevention of migraine symptomatology. 26 -28 There is evidence that migraine has a possible genetic basis. 29 -31 Migraineurs are more likely to have affected first-degree relatives, and for some forms of migraine (eg, familial hemiplegic migraine), specific genes have been identified. 26 In the present study, family history of migraine was a strong independent predictor of migraine, consistent with prior reports.
Although the underlying pathobiology is incompletely understood, increasing evidence suggests that cortical spreading depression, a slow propagating wave of neuronal depolarization followed by neural suppression, is the underlying substrate for migraine. 26, 28 Headache then results from activation of nociceptive afferents and release of neuropeptides. 32 It is possible that underlying genetic factors, modulated by environmental triggers, result in cortical spreading depression and an attack of migraine. In addition, there is some epidemiological evidence to suggest that migraineurs may have a higher cardiovascular risk profile than nonmigraineurs, and this is consistent with our finding of an association of migraine with family history of cerebrovascular disease. 33 Although it remains speculative, it has been suggested that migraine may be associated with endothelial dysfunction. 34 Some strengths of the present study should be highlighted. The present case-control study enrolled patients with migraine headaches diagnosed by neurologists in a headache clinic. Unlike prior observational studies, we excluded patients with a history of cerebrovascular disease or paradoxical embolism to avoid enrollment of subjects with risk for PFO other than migraine alone. With the exception of race, which was not a significant predictor in the multivariable model, control subjects represented a similar population as that from which the case subjects were sampled. Tests to detect PFO were performed and reported in a blinded manner, which decreased the chance of misclassification bias due to the lack of a "gold standard" test.
The present study should also be evaluated in the context of some limitations. We used a combination of TTE and TCD to diagnose PFO instead of transesophageal echocardiogram. Both TTE and TCD have been shown to have high sensitivity and specificity for diagnosis of right-to-left cardiac shunts compared with transesophageal echocardiogram. 21, 35, 36 Transesophageal echocardiogram is more sensitive and specific than either study but is a semi-invasive technique that requires sedation. We required both TTE and TCD to be positive to meet our case definition to increase specificity, but this possibly resulted in underestimation of rates. Although there is the potential that some individuals with PFO were PFO was not a significant predictor (adjusted OR 1.7, 95% CI 0.7 to 4.0, Pϭ0.18). Other variables considered were demographic factors (race, ethnicity), stratified on the matching factors of age and sex. falsely negative, the high specificity of the combined tests would likely increase the likelihood of finding a true association with migraine, if one existed. Nevertheless, in a sensitivity analysis, we considered the alternate, inclusive diagnosis of PFO based on either test being positive, which reached the same conclusion as the primary analysis. Finally, the results of the present study apply to the source population being studied and are not generalizable to adults with known history of cerebrovascular disease, paradoxical embolism, decompression illness, intracranial hemorrhage, intracranial mass, seizure disorder, organic central nervous system disease, headache as a result of traumatic head or neck injury, alcohol or substance abuse, uncontrolled hypertension, or known pregnancy.
Conclusions
We found no association between migraine headaches and the presence of PFO in this large case-control study nor any association between migraine severity and PFO size. Investigation of alternative mechanisms of migraine may offer novel approaches to the prevention and alleviation of migraine symptoms.
